Iodide

Iodide

SCHEMBL3694471

I.I.N=P(c1ccccc1)(c1ccccc1)c1ccccc1.N=P(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA5A P35218 1/20 0.41
ESR1 P03372 3/20 0.36
ESR2 Q92731 2/20 0.36
CFTR P13569 1/20 0.36
ALDH1A1 P00352 6/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
GAA P10253 2/20 0.35
ALOX12 P18054 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
HTT P42858 2/20 0.35
MAPT P10636 1/20 0.35
ALPG P10696 1/20 0.35
NPY1R P25929 1/20 0.35
NPY2R P49146 1/20 0.35
ALOX15 P16050 2/20 0.33
TSHR P16473 2/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL27336456 1.00 CA2 (0.41) CA2CA4CA5AESR1ESR2
SCHEMBL361668 0.97 CA2 (0.43) CA2CA4CA5AESR1ESR2
Hydrochloric Acid SCHEMBL996153 0.93 CA2 (0.41) CA2CA4CA5AESR1ESR2
SCHEMBL6316218 0.93 CA2 (0.41) CA2CA4CA5AESR1ESR2
Bromide SCHEMBL2185231 0.93 CA2 (0.41) CA2CA4CA5AESR1ESR2
Hydrochloric Acid SCHEMBL2582115 0.93 CA2 (0.41) CA2CA4CA5AESR1ESR2
SCHEMBL10710709 0.93 CA2 (0.41) CA2CA4CA5AESR1ESR2
Fluoride SCHEMBL11191593 0.93 CA2 (0.41) CA2CA4CA5AESR1ESR2
Water SCHEMBL7532602 0.93 CA2 (0.41) CA2CA4CA5AESR1ESR2
Carbon Monoxide SCHEMBL10931516 0.85 CA2 (0.42) CA2CA4CA5AESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9295981-B2 Method for producing ester compound by reacting an unsaturated organic compound and a formic acid ester in the presence of a catalyst system containing a ruthenium compound, a cobalt compound and a halide salt HITACHI CHEMICAL COMPANY, LTD. (JP) 2016-03-29 US disclosed
US-8653301-B2 Tricyclodecane monomethanol monocarboxylic acid and derivatives thereof HITACHI CHEMICAL COMPANY, LTD. (JP) 2014-02-18 US disclosed
US-20140031579-A1 METHOD OF PRODUCING NORBORNANEDICARBOXYLIC ACID ESTER NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2014-01-30 US disclosed
EP-2492258-A1 METHOD FOR MANUFACTURING A TRICYCLODECANE MONO-METHANOL MONOCARBOXYLIC ACID DERIVATIVE Hitachi Chemical Company, Ltd. (JP) 2012-08-29 EP disclosed
US-20120203026-A1 METHOD FOR MANUFACTURING TRICYCLODECANE MONO-METHANOL MONOCARBOXYLIC ACID DERIVATIVE NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2012-08-09 US disclosed
EP-2474519-A1 TRICYCLODECANE MONOMETHANOL MONOCARBOXYLIC ACID AND DERIVATIVES THEREOF Hitachi Chemical Company, Ltd. (JP) 2012-07-11 EP disclosed
US-20120157705-A1 TRICYCLODECANE MONOMETHANOL MONOCARBOXYLIC ACID AND DERIVATIVES THEREOF HITACHI CHEMICAL COMPANY, LTD. (JP) 2012-06-21 US disclosed
EP-2460785-A1 METHOD FOR PRODUCING ESTER COMPOUND Hitachi Chemical Company, Ltd. (JP) 2012-06-06 EP disclosed
US-20120123146-A1 METHOD FOR PRODUCING ESTER COMPOUND HITACHI CHEMICAL COMPANY, LTD. (JP) 2012-05-17 US disclosed
US-4703064-A FROM HYDROGEN AND CARBON MONOXIDE, USING RUTHENIUM CARBONYL COMPLEXES UNION CARBIDE CORPORATION (US) 1987-10-27 US disclosed
EP-0120462-A1 Accelerators for vulcanizing vinylidene fluoride elastomeric copolymers Montedison S.p.A. (IT) 1984-10-03 EP disclosed
US-4460709-A Process for producing oxygen-containing organic compounds AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) 1984-07-17 US disclosed
US-4434247-A FROM HYDROGEN AND CARBON MONOXIDE, RUTHENIUM CARBONYL UNION CARBIDE CORPORATION (US) 1984-02-28 US disclosed
EP-0085191-A1 Continuous process for producing alcohols UNION CARBIDE CORPORATION (US) 1983-08-10 EP disclosed
EP-0084682-A1 Process for producing alcohols UNION CARBIDE CORPORATION (US) 1983-08-03 EP disclosed
EP-0075937-A1 Process for producing alcohols UNION CARBIDE CORPORATION (US) 1983-04-06 EP disclosed
EP-0013008-B1 PROCESS FOR PRODUCING ALCOHOLS UNION CARBIDE CORPORATION (US) 1983-03-16 EP disclosed
EP-0068498-A1 Process for producing alcohols UNION CARBIDE CORPORATION (US) 1983-01-05 EP disclosed
EP-0055668-A1 Process for the production of ethylene glycol from synthesis gas in the presence of a ruthenium carbonyl complex UNION CARBIDE CORPORATION (US) 1982-07-07 EP disclosed
EP-0048980-A1 Continuous process for the manufacture of ethylene glycol UNION CARBIDE CORPORATION (US) 1982-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120203026-A1 METHOD FOR MANUFACTURING TRICYCLODECANE MONO-METHANOL MONOCARBOXYLIC ACID DERIVATIVE MCCC2, HACL2, HPD CA2 61/4885CA4 149/4885CA5A 84/4885
US-20120157705-A1 TRICYCLODECANE MONOMETHANOL MONOCARBOXYLIC ACID AND DERIVATIVES THEREOF MCCC2, HADHA, MLYCD CA2 849/4885CA4 956/4885CA5A 279/4885
US-20140031579-A1 METHOD OF PRODUCING NORBORNANEDICARBOXYLIC ACID ESTER HSD11B2, HSD17B12, HSD11B1 CA2 502/4885CA4 442/4885CA5A 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.